AI-generated summary
The authors report a prospective French study of the CareMin650 photobiomodulation device in 72 patients receiving radiotherapy for head and neck or breast cancer, used to prevent or treat mucositis and skin dermatitis. No device-related adverse events were reported, and lesions improved or stabilized in 71% of treated patients. The study was non-comparative and the efficacy results are described by the authors as preliminary.
- Participants
- 72
- Who or what was studied
- Patients with head and neck cancer or breast cancer receiving radiotherapy, treated prophylactically or curatively
- Limits stated in the abstract
- The study was non-comparative, with efficacy results described by the authors as preliminary.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Energy density (fluence)
- 3 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Oral mucositis, GRADE, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.